Agios Pharma (AGIO) Reports Updated Data for Mitapivat from Extension Phase of DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
Go back to Agios Pharma (AGIO) Reports Updated Data for Mitapivat from Extension Phase of DRIVE PK Study in Patients with Pyruvate Kinase Deficiency| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 35.10 +0.94 (2.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.16 | 52 Week High | $71.49 | |||
| Open | $34.30 | 52 Week Low | $33.50 | |||
| Day High | $35.53 | P/E | N/A | |||
| Day Low | $34.30 | EPS | $-1.18 | |||
| Volume | 1,378,941 | |||||
